Private company

Marinus Pharmaceuticals (United States)

In its 2024 annual report the company says: “We are a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY® (ganaxolone). We have an exclusive collaboration agreement with Orion Corporation (Orion) for European commercialization of ganaxolone for ZTALMY.”4 It was founded in 2003.1 It is headquartered in Radnor.1

Last updated Oct 20, 2026.

Overview

Jan 1, 2003Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersRadnor1
  • Websitewww.marinuspharma.com
  • Incorporated inDE3
  • Business address5 Radnor Corporate Center Suite 500, 100 Matsonford Rd, Radnor, Pa 190873
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY® (ganaxolone). On March 18, 2022, the U.S. Food and Drug Administration (FDA) approved our new drug application (NDA) for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. ZTALMY, our first FDA approved product, became available for commercial sale and shipment in the third quarter of 2022. On July 28 , 2023, the European Commission (EC) granted marketing authorization for ZTALMY for the adjunctive treatment of epileptic seizures associated with CDD in patients two to 17 years of age. ZTALMY may be continued in patients …4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-424.3%Operating margin5
-456.3%Net margin5
21.6%Revenue growth, 20235
-843.5%Return on equity5
4.47×Debt to equity5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development56¢$99.4M
  • Selling, general and admin34¢$61.2M
  • Interest9¢$16.9M
  • Income tax1¢$1.5M

Out of $31.0M in revenue.5 The company lost money this year.

Financial statements

Revenue65$31.0M in 2023+1704% since 2020
0$10.0M$20.0M$30.0M$40.0M2020: $1.7M$1.7M20202021: $9.0M$9.0M2021+423%2022: $25.5M$25.5M2022+183%2023: $31.0M$31.0M2023+22%
Operating income7896105-$131.5M in 2023+590% since 2017
-$150.0M-$100.0M-$50.0M02017: -$19.0M-$19.0M20172018: -$37.2M-$37.2M2018+95%2019: -$54.4M-$54.4M2019+46%2020: -$67.9M-$67.9M2020+25%2021: -$96.9M-$96.9M2021+43%2022: -$112.8M-$112.8M2022+16%2023: -$131.5M-$131.5M2023+17%
Net income7896105-$141.4M in 2023+648% since 2017
-$150.0M-$100.0M-$50.0M02017: -$18.9M-$18.9M20172018: -$36.7M-$36.7M2018+94%2019: -$54.1M-$54.1M2019+47%2020: -$67.5M-$67.5M2020+25%2021: -$98.8M-$98.8M2021+46%2022: -$19.8M-$19.8M2022−80%2023: -$141.4M-$141.4M2023+614%
Fiscal year2017201820192020202120222023
Revenue$1.7M6$9.0M6$25.5M5$31.0M5
Cost of revenue$1.5M6
Research and development$12.4M7$28.4M8$43.0M9$51.1M6$73.5M10$79.9M5$99.4M5
Selling, general and admin$37.3M10$56.8M5$61.2M5
Operating expenses$112.3M10$138.3M5$162.5M5
Operating income-$19.0M7-$37.2M8-$54.4M9-$67.9M6-$96.9M10-$112.8M5-$131.5M5
Interest$159.0K7$2.6M10$10.7M5$16.9M5
Income before tax-$98.8M10-$16.4M5-$142.9M5
Income tax$3.4M5-$1.5M5
Net income-$18.9M7-$36.7M8-$54.1M9-$67.5M6-$98.8M10-$19.8M5-$141.4M5
Earnings per share-$2.806-$2.6910-$0.515-$2.635
Earnings per share (diluted)-$2.806-$2.6910-$0.515-$2.635
Shares (weighted, basic)36.7M shares1039.1M shares553.7M shares5
Shares (weighted, diluted)36.7M shares1039.1M shares553.7M shares5

Compare Marinus Pharmaceuticals (United States) with another company

Corporate structure

Marinus Pharmaceuticals (United States) sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Marinus Pharmaceuticals (United States)

  • Beryl Capital Management LLC Filed SCHEDULE 13G/A on Marinus Pharmaceuticals (United States), latest May 15, 2025 (2 filings since Jan 7, 2025)
  • Morgan Stanley Filed SCHEDULE 13G/A on Marinus Pharmaceuticals (United States), latest Mar 6, 2025 (2 filings since Feb 4, 2025)
  • Panacea Innovation Ltd Filed SCHEDULE 13G/A on Marinus Pharmaceuticals (United States), latest Feb 14, 2025 (2 filings since Nov 1, 2024)
  • TANG CAPITAL PARTNERS LP Filed SCHEDULE 13G/A on Marinus Pharmaceuticals (United States), latest Feb 14, 2025 (2 filings since Apr 19, 2024)
  • Sofinnova Investments, Inc. Filed SCHEDULE 13G/A on Marinus Pharmaceuticals (United States), latest Feb 12, 2025 (2 filings since Nov 14, 2024)
  • Franklin Templeton Investments Filed SCHEDULE 13G/A on Marinus Pharmaceuticals (United States), latest Feb 11, 2025 (3 filings since Feb 6, 2024)
  • MONTANOVA CAPITAL, LLC Filed SCHEDULE 13G on Marinus Pharmaceuticals (United States), latest Feb 11, 2025 (5 filings since Feb 11, 2022)
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on Marinus Pharmaceuticals (United States), latest Jan 31, 2025 (3 filings since Nov 4, 2024)
  • Avoro Capital Advisors LLC Filed SC 13G/A on Marinus Pharmaceuticals (United States), latest Nov 14, 2024 (4 filings since Feb 11, 2022)
  • Cormorant Asset Management, LP Filed SC 13G/A on Marinus Pharmaceuticals (United States), latest Nov 14, 2024 (3 filings since Oct 10, 2023)
  • EVENTIDE ASSET MANAGEMENT, LLC Filed SC 13G/A on Marinus Pharmaceuticals (United States), latest Nov 14, 2024 (3 filings since Feb 14, 2023)
  • Prudential Financial Filed SC 13G/A on Marinus Pharmaceuticals (United States), latest Nov 14, 2024 (2 filings since Feb 13, 2024)
  • Marinus Pharmaceuticals (United States) Radnor

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Marinus Pharmaceuticals (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$5.7M5 Dec 31, 2023$5.7M5 Dec 31, 2022+0.9%
Accumulated depreciation$1.9M5 Dec 31, 2023$1.5M5 Dec 31, 2022+30.7%
Property and equipment, net$3.8M5 Dec 31, 2023$4.2M5 Dec 31, 2022−9.3%
Operating-lease assets (leased space)$1.0M5 Dec 31, 2023$1.3M5 Dec 31, 2022−23.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$120.6M5 Dec 31, 2023$240.6M5 Dec 31, 2022−49.9%
Marketable securities, current$29.7M5 Dec 31, 2023
Debt securities available for sale$29.7M5 Dec 31, 2023

Inventory

ItemLatestA year beforeChange
Inventory, total$2.4M5 Dec 31, 2023$77.0K5 Dec 31, 2022+3033.8%

Leadership

Who has led Marinus Pharmaceuticals (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Scott Braunstein2019–2025

Chair

  1. Scott Braunstein2019–2025

Chief financial officer

  1. Edward F. Smith2014–2021
  2. Steven Pfanstiel2021–2025

Chief operating officer

  1. Steven Pfanstiel2023–2025
20052010201520202025
Board members and other officers (22)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorCharles E. Austin named Apr 4, 202240
  • DirectorSantiago E. Arroyo, M.D., Ph.D. named Apr 4, 202240
  • DirectorSaraswathy M. Nochur, Ph.D. named Apr 4, 202240
  • DirectorSeth H.Z. Fischer named Apr 4, 202240

Former names

  • MARINUS PHARMACEUTICALS INCOct 22, 2003 to Mar 31, 20223

Timeline

  1. Feb 11, 20258-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights41
  2. Dec 30, 20248-K Entered a material agreement; Ended a material agreement42
  3. Dec 30, 20248-K Entered a material agreement; Executive or director change; Regulation FD disclosure43
  4. Dec 23, 20248-K Executive or director change44
  5. Dec 10, 20248-K Listing notice or transfer45
  6. Nov 15, 20248-K Executive or director change46
  7. Nov 12, 20248-K Results of operations47
  8. Oct 24, 20248-K Other events48
  9. Oct 2, 20248-K Other events49
  10. Sep 20, 20248-K Other events50
  11. Aug 13, 20248-K Results of operations; Other events51
  12. Jun 17, 20248-K Other events52
  13. Dec 13, 2019New chief executive Scott Braunstein becomes CEO13
  14. Jan 1, 2003Founded Founded1

Calendar

When it reported results

  1. Nov 12, 2024Reported quarterly or annual results47
  2. Aug 13, 2024Reported quarterly or annual results51
  3. May 8, 2024Reported quarterly or annual results53
  4. Apr 15, 2024Reported quarterly or annual results54
  5. Mar 5, 2024Reported quarterly or annual results55
  6. Jan 4, 2024Reported quarterly or annual results56
  7. Nov 7, 2023Reported quarterly or annual results57
  8. Aug 10, 2023Reported quarterly or annual results58

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

260 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 61 major events, 92 insider forms, 53 large holders, 1 private raises, 40 other. The latest 20:

  1. May 15, 2025SCHEDULE 13G/A EDGAR
  2. Mar 6, 2025SCHEDULE 13G/A EDGAR
  3. Feb 21, 202515-12G EDGAR
  4. Feb 14, 2025SCHEDULE 13G/A EDGAR
  5. Feb 14, 2025SCHEDULE 13G/A EDGAR
  6. Feb 13, 2025EFFECT EDGAR
  7. Feb 13, 2025EFFECT EDGAR
  8. Feb 13, 2025EFFECT EDGAR
  9. Feb 12, 2025SCHEDULE 13G/A EDGAR
  10. Feb 11, 202525-NSE EDGAR
  11. Feb 11, 20254 OWNERSHIP DOCUMENT EDGAR
  12. Feb 11, 20254 OWNERSHIP DOCUMENT EDGAR
  13. Feb 11, 20254 OWNERSHIP DOCUMENT EDGAR
  14. Feb 11, 20254 OWNERSHIP DOCUMENT EDGAR
  15. Feb 11, 20254 OWNERSHIP DOCUMENT EDGAR
  16. Feb 11, 20254 OWNERSHIP DOCUMENT EDGAR
  17. Feb 11, 20254 OWNERSHIP DOCUMENT EDGAR
  18. Feb 11, 20254 OWNERSHIP DOCUMENT EDGAR
  19. Feb 11, 20254 OWNERSHIP DOCUMENT EDGAR
  20. Feb 11, 20254 OWNERSHIP DOCUMENT EDGAR

The 260 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 1 buys and 25 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 21, 2025Ezickson ElanDirectorSale1,600$0.54$864Form 4
Jan 21, 2025Johnson MarvinDirectorSale1,610$0.54$869Form 4
Aug 14, 2024Braunstein ScottCHAIRMAN AND CEOBuy5,933$1.10$6.5KForm 4
Aug 5, 2024Shafer ChristinaCHIEF COMMERCIAL OFFICERSale3,820$1.14$4.4KForm 4
Aug 5, 2024Pfanstiel StevenCFO AND COOSale4,657$1.13$5.3KForm 4
Aug 5, 2024MANNING MARTHA ESVP, GEN. COUNSEL & CORP. SEC.Sale3,621$1.13$4.1KForm 4
Aug 5, 2024Hulihan JosephCHIEF MEDICAL OFFICERSale4,828$1.13$5.5KForm 4
Aug 5, 2024Braunstein ScottCHAIRMAN AND CEOSale12,145$1.13$13.7KForm 4
Feb 20, 2024Shafer ChristinaCHIEF COMMERCIAL OFFICERSale2,153$9.56$20.6KForm 4
Feb 20, 2024MANNING MARTHA ESVP, GEN. COUNSEL & CORP. SEC.Sale1,894$9.57$18.1KForm 4
Feb 16, 2024Hulihan JosephCHIEF MEDICAL OFFICERSale2,814$9.98$28.1KForm 4
Feb 16, 2024Pfanstiel StevenCFO AND COOSale3,092$9.97$30.8KForm 4
Feb 16, 2024Braunstein ScottCHAIRMAN AND CEOSale11,850$9.94$117.8KForm 4
Aug 8, 2023Shafer ChristinaCHIEF COMMERCIAL OFFICERSale11$8.93$98Form 4
Aug 8, 2023Braunstein ScottCHAIRMAN AND CEOSale30$8.94$268Form 4
Aug 8, 2023Pfanstiel StevenCFO AND COOSale14$8.93$125Form 4
Aug 8, 2023MANNING MARTHA ESVP, GEN. COUNSEL & CORP. SEC.Sale11$8.93$98Form 4
Aug 8, 2023Hulihan JosephCHIEF MEDICAL OFFICERSale13$8.93$116Form 4
Aug 7, 2023Shafer ChristinaCHIEF COMMERCIAL OFFICERSale2,385$9.52$22.7KForm 4
Aug 7, 2023Braunstein ScottCHAIRMAN AND CEOSale6,413$9.55$61.2KForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Mar 29, 2022Raised $1.2 million in a private offering of equity Form D: 1 investor so far Form D

SEC filer profile

How Marinus Pharmaceuticals (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMARINUS PHARMACEUTICALS, INC.2
  • CIK0001267813
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address5 Radnor Corporate Center Suite 500, 100 Matsonford Rd, Radnor, PA 190872
  • Phone484-801-46702
  • Shares outstanding55,185,622 as of Nov 5, 202412
  • Public float$545.2M as of Jun 30, 20235
  • On EDGAR sinceOct 22, 20032
  • Filings652 in all: 4 (199), 8-K (147), SC 13G/A (54), 10-Q (32), 3 (31), SC 13G (30), 424B5 (15), CORRESP (15)2
    All 46 form types

    4/A (11), DEF 14A (11), 10-K (10), EFFECT (9), SCHEDULE 13G/A (9), S-8 (8), S-8 POS (8), DEFA14A (7), UPLOAD (6), S-3 (5), D (4), POS AM (3), REGDEX (3), SC 13D/A (3), SCHEDULE 13G (3), CT ORDER (2), PRE 14A (2), S-1/A (2), SC 13D (2), SC 14D9/A (2), SC TO-T/A (2), 10-Q/A (1), 144 (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERTNAS (1), D/A (1), DRS (1), DRSLTR (1), REGDEX/A (1), S-1 (1), S-3/A (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 5, 2024
    Quarterly report (10-Q) Nov 12, 2024
    Proxy statement (DEF 14A) Apr 4, 2024
    Latest 8-K (8-K) Feb 11, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
    SEC EDGAROther events
  49. 49
    SEC EDGAROther events
  50. 50
    SEC EDGAROther events
  51. 51
  52. 52
    SEC EDGAROther events
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78